Omar Khader, Aaram
van Trier, Tinka
van der Brug, Sander
Liem, An-ho
Groenemeijer, Bjorn E.
Schut, Astrid
Jorstad, Harald T.
Martens, Fabrice M.A.C.
Alings, Marco A.M.W.
Funding for this research was provided by:
Sanofi-Aventis Deutschland
Article History
Accepted: 14 December 2023
First Online: 26 January 2024
Declarations
:
: A.-h. Liem: co-author of the Dutch cardiovascular risk management guidelines (CVRM). H.T. Jorstad: Editor for NEHJ. F.M.A.C. Martens: co-author of the Dutch cardiovascular risk management guidelines (CVRM). A.M.W. Alings: consulting fees from Sanofi. A. Omar Khader, T. van Trier, S. van der Brug, B.E. Groenemeijer and A. Schut declare that they have no competing interests.
: The trial was reviewed and approved by the Institutional Review Board, i.e. the ethics committee (Medical Research Ethics Committees United (MEC-U)—66879.100.18_R18.063). All patients signed written informed consent at inclusion.